Search
-
Ipsos launches GLP-1 PersonaBot, designed to support companies’ understanding of the consumer obesity treatment market
Ipsos’ latest AI-powered innovation offers unparalleled insights into the fast-moving consumer obesity treatment market – while reinforcing Ipsos’ position at the forefront of AI applications in market research.
-
Healthcare vs Evolution: Can GLP-1s Rewrite Our Evolutionary Story?
Our evolutionary tale began 6 million years ago, when humans were programmed to hoard calories in a world of scarcity. Today, that ancient wiring has become our greatest health risk.
-
Ipsos Answers Esomar’s Questions to help online research buyers
The primary aim of the ESOMAR's Questions is to increase transparency and raise awareness of the key issues for researchers to consider when deciding whether an online sampling approach is fit for their purpose.
-
The Rising Tide of Private Labels: How name brands can stay afloat
By embracing innovation, building strong brand equity, enhancing the customer experience, and adopting strategic partnerships and omnichannel strategies, name brands can thrive in the face of competition.
-
Bringing Healthcare Segmentations to Life: The Dawn of the GenAI-Powered Persona
Enter the age of generative AI, ushering in a new era of possibility with the advent of the persona bot – a tool with the potential to revolutionise how pharmaceutical companies activate and leverage segmentation data.
-
A Dose of Digital: Can Pharma Make DTx a Healthy Business?
Digital therapeutics (DTx) are emerging as a potential game-changer in healthcare, offering evidence-based digital interventions to help prevent, manage, or treat specific conditions.
-
Nationwide: Reaping the rewards of demonstrating empathy
Recent research conducted by Ipsos across numerous categories brought to light the importance of Expectations, Context, and Empathy in driving brand choice.